



March 20, 2023

Aprepitant and Lidocaine/Prilocaine Recalled by Sandoz

Effective Date: March 9, 2023

On March 9, 2023, Sandoz announced a voluntary recall of two lots of Aprepitant 125 mg capsules and nine lots of Lidocaine/Prilocaine 2.5%/2.5% cream because the packaging is not child-resistant, posing a risk of harm if children ingest the drugs or put the cream on their skin.

Per Sandoz, the recall is not a result of any quality or safety concerns with the medications for their intended use, so patients should continue using the medication as directed. However, due to the risk of harm to children, consumers should immediately secure the medication out of the sight and reach of children.

Optum Rx notifies members who may be affected by this recall. These members were provided information to help them identify if their product is being recalled and advised to contact Sandoz for free, child-resistant, resealable pouches in which to store the affected medication out of the sight and reach of children.

These members may inquire about the Aprepitant or Lidocaine/Prilocaine prescription(s) you dispensed.

Contact Sandoz at **866-300-2207** (8:00 AM – 5:00 PM ET, Monday through Friday) to obtain free child-resistant, resealable pouches to store the recalled drugs. You can also call Sandoz at **800-525-8747** (8:30 AM – 5:00 PM ET, Monday through Friday) for more information about the recall.

Aprepitant and Lidocaine/Prilocaine Recalled by Sandoz

Product Description	NDC #	Lot/Batch #
Aprepitant 125 mg capsules	0781-2323-68 (carton)	LK3209 (4/2024)
	0781-2323-06 (blister pack)	LC6454 (12/2023)
Lidocaine/Prilocaine 2.5%/2.5% cream	0168-0357-56 (carton) 0168-0357-55 (carton) 0168-0357-05 (tube)	LA2782 (3/2023)
		LA2784 (3/2023)
		LV0667 (3/2024)
		LX5350 (3/2024)
		MA1640 (3/2024)
		MB3205 (4/2024)
		LA2785 (3/2023)
		LR9041 (11/2023)
		MB3209 (4/2024)

Reference:

Sandoz Product Safety Notice. Important Drug Recall: Aprepitant Capsules 125 mg, Lidocaine and Prilocaine 2.5%/2.5% Cream. Sandoz website. <https://www.us.sandoz.com/patients-customers/product-safety-notice>. Accessed March 15, 2023.

Please distribute immediately.

For questions regarding communications, contact the Pharmacy Provider Communications team: pharmacyprovidercommunications@optum.com
 All Optum trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners. This document contains information that is considered proprietary to OptumRx and should not be reproduced without express written consent of OptumRx. ©2023 Optum, Inc. All rights reserved.